News >

Entrectinib Effective in Pancreatic Cancer Subgroup

Angelica Welch
Published: Monday, Jan 29, 2018

Michael J. Pishvaian, MD, PhD

Michael J. Pishvaian, MD, PhD
In a study of patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions, investigators evaluated the selective TRK and ROS1 inhibitor entrectinib, which is both potent and active in patients with CNS metastases, where results showed early signs of antitumor activity.

, Pishvaian, director of the Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discussed the findings with entrectinib in this population, as well as the potential implications of widespread molecular testing in pancreatic cancer.

OncLive: Can you provide some background on this study?

Pishvaian: Patients with pancreatic cancer obviously have limited therapeutic options. We know that chemotherapy can be of benefit—we all use chemotherapy regularly, but we are certainly looking for something better. There is a relatively small population of patients who have defined molecular actionable alterations, although that list is growing. There are no approved therapies that are targeted to metastatic pancreatic cancer, except for the small subgroup of patients who are known to have microsatellite instability-high pancreatic cancer, for which pembrolizumab (Keytruda) may be of benefit. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x